- Spark Newswire

1 minute read

First Patient Dosed in Citius Pharma’s Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Today, 5:58 AM

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.

CTXR

1 minute read

Prothena Receives FDA Fast Track Designation for PRX012 for the Treatment of Alzheimer’s Disease

By Ragothaman Srinivasan

Today, 5:58 AM

Prothena Corporation plc (NASDAQ: PRTA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-amyloid beta (Aβ) antibody therapy drug candidate PRX012 for the treatment of Alzheimer's disease.

PRTA

1 minute read

U.S. FDA Grants Fast Track designation To Ofra-Vec (VB-111) For Platinum-Resistant Ovarian Cancer

By Ragothaman Srinivasan

Today, 5:58 AM

VBL Therapeutics (NASDAQ: VBLT) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its drug candidate Ofra-Vec (VB-111) in combination with Paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

VBLT

1 minute read

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint

By Ragothaman Srinivasan

Today, 5:58 AM

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

PTGX

1 minute read

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines

By Ragothaman Srinivasan

Today, 5:58 AM

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for Injection for the treatment of patients with moderate to severe glabellar lines.

RVNC

1 minute read

FDA Clears Moleculin’s IND Application To Conduct Phase 1 Study Of WP1066 For Recurrent Malignant Glioma

By Ragothaman Srinivasan

Today, 5:58 AM

Moleculin Biotech, Inc. (NASDAQ: MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma.

MBRX

1 minute read

FDA clears Moleculin’s IND application to Conduct Phase 1 Study of WP1066 for Recurrent Malignant Glioma

By Ragothaman Srinivasan

Today, 5:58 AM

Moleculin Biotech, Inc. (MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma The company plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label clinical study of oral WP1066 in adult patients.

MBRX